Cipla Acquires Elores

Cipla Acquires Elores

The Pharma giant Cipla Limited announces the acquisition of a novel and patented anti-infective product, Elores, from Venus Remedies Limited.

This acquisition would further strengthen Cipla’s presence in the branded Indian critical care market and as a part of the company’s agenda to contribute to the fight against AMR.

Cipla Acquires Elores – What is Elores?

Elores is a novel combination of Ceftriaxone- a third-generation beta-lactam cephalosporin, Sulbactam- a beta-lactamase inhibitor, and Disodium EDTA- an Antibiotic Resistance Breaker indicated for the treatment of life-threatening infections caused by gram-negative bacteria.

It preserves the efficacy of the antibiotic using appropriate Antibiotic Resistance Breakers (ARBs). This product was launched in India across select tertiary care hospitals in 2013 after approval from the Drug Controller General of India.

Anti Microbial Resistance has emerged as a crucial threat to public health. At present, it is estimated that as many as 10 million individuals ascross the world could die annually from complications related to AMR. India carries one of the most significant burdens of drug-resistant pathogens worldwide.

Cipla Acquires Elores – Cipla The Anti-Microbial Leader

In India, Cipla has a long history of antibiotic development. Right from ampicillin in the 1970s to quinolones in the 1990s. Recently, Cipla introduced the beneficial antibiotic- colistin in India. Today, Cipla is the market leader in the anti-biotic segment in India and has an extensive portfolio of oral and invasive anti-microbial brands that serve over 20 million patients every year. Elores will strengthen Cipla’s play in branded anti-infectives.

Umang Vohra, Managing Director, and Global Chief Executive Officer, Cipla, said that Cipla has consistently been fighting for Anti Microbial Resistance. Elores underscores the company’s commitment to anti-microbial stewardship and is a significant addition to our branded portfolio of anti-infectives in India. He added that Cipla Acquires Elores is a new generation antibiotic and useful addition to Cipla’s collection.

See Also
Study Helps Identify Medications Safe To Treat COVID-19

According to Mr. Vohra, Elores will improve patient access to innovative quality medicines and help patients battle life-threatening resistance at critical junctures.

Source

Author: Rahul Mishra

Upload your CV to Rasayanika Talent Pool

LEAVE A REPLY

Please enter your comment!
Please enter your name here